Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalNeurologyEpilepsyTrial Update

Study on Social Feedback's Impact on Intracranial EEG in Epilepsy Patients

This clinical trial explores the intersection of social feedback and neural responses in epilepsy patients, potentially reshaping patient engagement strategies. Insights gained could lead to improved treatment outcomes and inform clinical practices in neurology.

Published: July 5, 2026
Updated: July 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Epilepsy
Asset: Study
Trial SummaryCLN

Phase III

Neurology / Epilepsy

Status

Active

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Strategic implication

This clinical trial explores the intersection of social feedback and neural responses in epilepsy patients, potentially reshaping patient engagement strategies. Insights gained could lead to improved treatment outcomes and inform clinical practices in neurology.

Why it matters

This clinical trial explores the intersection of social feedback and neural responses in epilepsy patients, potentially reshaping patient engagement strategies. Insights gained could lead to improved treatment outcomes and inform clinical practices in neurology.

What changed

Trial Update

Analysis

A clinical trial is assessing how social feedback influences neural recordings in epilepsy patients during surgery.

This clinical trial explores the intersection of social feedback and neural responses in epilepsy patients, potentially reshaping patient engagement strategies. Insights gained could lead to improved treatment outcomes and inform clinical practices in neurology.

Monitor results from the trial for potential implications on patient care practices and neural response patterns.

Related companies & assets

Assets

  • Study →
  • epilepsy patients →
  • neurology care practices →

Sources & Humanexa intelligence

Source links

  • Study on Social Feedback's Impact on Intracranial EEG in Epilepsy Patients ↗

Related Humanexa pages

  • Study on Social Feedback's Impact on Intracranial EEG in Epilepsy Patients →

Related signals

Trial SummaryCLN

Phase III

Surgery / Thoracic

Status

Active

Signal Score

8.2

Clinicalhigh signal

Study on Intraoperative Chest Tube Removal in Thoracoscopic Wedge Resection

The study investigates the safety and feasibility of intraoperative chest tube removal during thoracoscopic wedge resection.

July 5, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / T Cell Non-Hodgkin Lymphoma

Status

Active

Signal Score

8.2

Clinicalhigh signal

Kyowa Kirin initiates first-in-human trial for KK2223 in T Cell Non-Hodgkin Lymphoma

Kyowa Kirin is conducting a first-in-human study to evaluate KK2223 in patients with relapsed or refractory T cell lymphoma.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.